University of California, Davis
The investigators want to study the impact CGM (continuous glucose monitoring) has on patients glycemic control as determined by time in range (TIR 70-180 mg/dL) in the Diabetic Kidney Transplant population.
Diabetes is one of the leading causes of End Stage Renal Disease (ESRD). Kidney transplantation is the best form of renal replacement therapy to date but requires that recipients of transplant organs maintain a complicated medication regimen in order to prevent graft loss. Their medications include lifelong immunosuppression, anti-microbials and other maintenance medications (i.e., anti-hypertensives, heart-protective regimens, bowel care, vitamins and pain medications). For many transplant patients, glycemic control in the immediate post-operative period can be an additional challenge. Glyce…
Inclusion Criteria: 1. Age 18 or above 2. Received a kidney transplant within the past year with functioning kidney (eGFR \> 30 mL/min 3. Person with Type 2 Diabetes and on insulin 4. Access to home wi-fi connection Exclusion Criteria: 1. Person with Type 1 Diabetes 2. Patients taking hydroxyurea 3. Patient unable to wear the Dexcom G6 device at all times for any reason 4. Must be able to test blood glucose with meter 4x a day when on blinded CGM. 5. Presence of clinically significant visual or cognitive impairment 6. Illiterate 7. Prisoners 8. Women who are pregnant, who plan to become pre…
access to continuous glucose monitoring in the Dexcom G6 arm 24/7
retrospective access to continuous glucose profile after 10 days of wear
Arctuva estimate
Verify or correct the compensation shown for this listing.